Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Declines By 74.3%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large decline in short interest in January. As of January 15th, there was short interest totalling 117,500 shares, a decline of 74.3% from the December 31st total of 457,500 shares. Based on an average trading volume of 3,580,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.8% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a research report on Wednesday, October 9th.

Institutional Investors Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new position in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. Institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Stock Performance

VRPX stock traded down $0.01 during mid-day trading on Thursday, hitting $0.31. The stock had a trading volume of 510,607 shares, compared to its average volume of 520,959. Virpax Pharmaceuticals has a 1-year low of $0.23 and a 1-year high of $5.48. The company has a fifty day moving average of $0.37 and a 200 day moving average of $0.68.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.